It was a big week for Medtronic (NYSE:MDT) and its Symplicity high blood pressure device, with the release of 2-year clinical data and a pair of regulatory developments for the renal denervation system.
The field of transcatheter mitral valve repair may move more quickly in pet populations than it does in human medicine, according to a presentation during this week’s American College of Cardiology conference in San Francisco.
Researchers are hard at work on a technology, called MitralSeal, they they hope to bring to market to treat mitral valve regurgitation in dogs.
Updated March 19, 2013, at 11:30 a.m. to reflect that the quote in paragraph 6 came from an ACC press release, not an Edwards press release.
MASSDEVICE ON CALL — The embargo breach that got Boston Scientific’s (NYSE:BSX) PREVAIL clinical trial results pulled from the lineup at the American College of Cardiology conference this weekend was "an honest mistake," according to the company, but conference organizers don’t regret canceling the presentation.
Updated March 9, 2013, at 8:30 p.m. PST with comment, slides from Boston Scientific.
"The good thing about bad news – it sells."
In the 1st study of its kind to examine the interaction between hybrid cars and implantable cardiac devices, researchers found that the electromagnetic waves generated by the green vehicles don’t pose a threat.
"Hybrid cards do not generated clinically relevant amounts of [electromagnetic interference]," according to a team of researchers from the Mayo Clinic of Arizona. "It is safe for patients with ICD to interact with hybrid cars."